RML Hospital Drug Recall: 10 Medicine Batches Pulled After Quality Failures in Delhi
NEW DELHI: Dr Ram Manohar Lohia Hospital has recalled 10 batches of medicines after eight batches failed analytical testing and two others were found with physical defects. The RML Hospital drug recall was set in motion through four notices issued between September 7 and 14, directing hospital departments and wards to stop using the affected stocks.
According to the Times of India, the affected medicines include sodium valproate, spironolactone, imipramine, adenosine, methyl ergometrine, metoprolol and isosorbide mononitrate. They are used for conditions including seizures, heart problems, abnormal heart rhythms and postpartum bleeding.
Eight Batches Failed Analytical Testing
The hospital classified three tablet batches and five injectable batches as “Not of Standard Quality” after analytical testing.
The tablets included sodium valproate gastro-resistant 200 mg, spironolactone 50 mg and imipramine 25 mg. The five injectable medicines were adenosine, methyl ergometrine, multivitamin injection, pheniramine maleate and ascorbic acid.
The findings form the main part of the RML Hospital drug recall, although the available reporting does not specify the precise laboratory parameter that each batch failed.
Two Tablet Batches Found In Powder Form
Two additional batches were withdrawn because of physical defects rather than analytical-test failures.
A September 9 notice flagged isosorbide mononitrate 20 mg tablets from batch ABT6711 after tablets were found in powder form inside their strip packaging. The batch was manufactured by Glowson India Labs Pvt Ltd in July 2026 and was listed with a June 2028 expiry date.
A similar problem was reported for metoprolol 50 mg, batch ABT6608, from the same manufacturer. Hospital departments were instructed to stop using both batches and return them to the store with documentation.
These findings are central to the Substandard medicine recall Delhi developments, although the two physically defective batches were separately identified from the eight batches classified as “Not of Standard Quality”.
Hospital Orders Immediate Withdrawal
RML’s inventory management section instructed the relevant wards and departments to withdraw the affected medicines and return them to designated drug units.
The notices covering the eight batches that failed testing required their return by September 18. The two batches showing physical defects were to be returned within three days of their respective notices.
The hospital also instructed staff to report any patient-related problems observed after use.
No Severe Adverse Effects Reported
RML officials said no severe adverse effects had been reported among end users in connection with the recalled batches as of the latest update. The hospital has also arranged alternative medicines to prevent interruptions in patient care.
Some medicine samples were supplied by M/s Jackson Laboratories Pvt Ltd, according to hospital officials quoted in the reporting. The available information does not establish that the supplier caused the quality failures.
The RML seizure cardiac drugs affected by the recall cover several different therapeutic uses rather than a single category. Sodium valproate is used for seizure disorders, while spironolactone and metoprolol are used in the management of cardiovascular conditions.
For patients, the Substandard medicine recall Delhi does not mean that every medicine of the same name is affected. The notices concern specific batches, making the batch number and packaging details important for identifying the recalled stock.
The RML seizure cardiac drugs recall remains a hospital-level quality action based on the reported test results and observed defects. Further regulatory or manufacturer-level action, if any, would depend on subsequent findings.
The RML Hospital drug recall therefore affects specific batches rather than all supplies of the medicines concerned.
